World's Best Scientists 2026 revealed!
Thierry Poynard

Thierry Poynard

Award Badge
Medicine
France
2023

D-Index & Metrics

Medicine

D-Index
144
Citations
92389
World Ranking
1426
National Ranking
32

Research.com Recognitions

  • 2023 - Research.com Medicine in France Leader Award

Overview

Thierry Poynard is affiliated with Sorbonne University in France and focuses primarily on medical research within the field of medicine, with particular attention to epidemiology, hepatology, oncology, cell biology, and general health professions.

Their research extensively covers key topics including liver disease diagnosis and treatment, hepatitis C virus research, liver disease and transplantation, endoplasmic reticulum stress and disease, autophagy in disease and therapy, patient-provider communication in healthcare, and global cancer incidence and screening.

Key published papers by Thierry Poynard include:

  • "Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis," 2020, Journal of Clinical Medicine
  • "ACBP/DBI neutralization for the experimental treatment of fatty liver disease," 2024, Cell Death and Differentiation
  • "WED-487 The blood-based SteatoTest-2 score identifies a previously invisible early steatosis phenotype," 2025, Journal of Hepatology
  • "Academia Europaea's guidelines for the visualization of clinical outcomes," 2025, Nature Medicine
  • "Publisher Correction: Academia Europaea's guidelines for the visualization of clinical outcomes," 2025, Nature Medicine

Thierry Poynard frequently publishes in the following venues:

  • Nature Medicine
  • Journal of Clinical Medicine
  • Cell Death and Differentiation
  • Journal of Hepatology

Collaborations have been established with several coauthors, including:

  • Laurent Castéra
  • Dominique Valla
  • Péter Hegyi
  • András Garami
  • Àlvar Agustí

Best Publications

  • An algorithm for the grading of activity in chronic hepatitis C

    Pierre Bedossa;Thierry Poynard

  • Natural history of liver fibrosis progression in patients with chronic hepatitis C

    Thierry Poynard;Pierre Bedossa;Pierre Opolon

  • Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

    Thierry Poynard;Patrick Marcellin;Samuel S Lee;Christian Niederau

  • Sampling variability of liver biopsy in nonalcoholic fatty liver disease.

    Vlad Ratziu;Frédéric Charlotte;Agnès Heurtier;Sophie Gombert

  • Biochemical markers of liver fibrosis in patients with hepatitis C virus infection : a prospective study

    Françoise Imbert-Bismut;Vlad Ratziu;Laurence Pieroni;Frederic Charlotte

  • Viral hepatitis B

    Ching Lung Lai;Vlad Ratziu;Man-Fung Yuen;Thierry Poynard

  • Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients

    Y Benhamou;M Bochet;V Di Martino;F Charlotte

  • Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

    Thierry Poynard;John McHutchison;Michael Manns;Christian Trepo

  • Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C

    John G. McHutchison;Michael Manns;Keyur Patel;Thierry Poynard

  • Liver fibrosis in overweight patients.

    Vlad Ratziu;Philippe Giral;Frederic Charlotte;Eric Bruckert

  • Viral hepatitis C

    Thierry Poynard;Man-Fung Yuen;Vlad Ratzin;Ching Lung Lai

  • Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression

    Gary L Davis;Miriam J Alter;Hashem El-Serag;Thierry Poynard

  • Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis.

    Brigitte Bernard;Jean-Didier Grangé;Eric Nguyen Khac;Xavier Amiot

  • Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C

    Thierry Poynard;Vlad Ratziu;Frédéric Charlotte;Zachary Goodman

  • Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

    Alexander J. Thompson;Andrew J. Muir;Andrew J. Muir;Mark S. Sulkowski;Dongliang Ge

  • Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

    T Poynard;V Leroy;M Cohard;T Thevenot

  • Extrahepatic manifestations of chronic hepatitis C

    Patrice Cacoub;Thierry Poynard;Pascale Ghillani;Frederic Charlotte

  • Liver Fibrosis in Viral Hepatitis: Noninvasive Assessment with Acoustic Radiation Force Impulse Imaging versus Transient Elastography

    Mireen Friedrich-Rust;Katrin Wunder;Susanne Kriener;Fariba Sotoudeh

  • Estimating future hepatitis C morbidity, mortality, and costs in the United States.

    John B. Wong;Geraldine M. Mcquillan;John G. Mchutchison;Thierry Poynard

  • Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

    Thierry Poynard;Patrick Marcellin;Samuel S. Lee;Christian Niederau

Frequent Co-Authors

Frédéric Charlotte
Frédéric Charlotte Université Paris Cité
Patrice Cacoub
Patrice Cacoub Sorbonne University
Stanislas Pol
Stanislas Pol Université Paris Cité
Philippe Mathurin
Philippe Mathurin University of Lille
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Robert P. Myers
Robert P. Myers University of Calgary
Laurent Alric
Laurent Alric Federal University of Toulouse Midi-Pyrénées

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring healthcare careers beyond traditional medicine can open a wide range of opportunities. For those interested in advanced nursing roles but who do not have a nursing background, direct entry nurse practitioner programs for non-nurses online offer a flexible route to becoming a nurse practitioner. These programs are accelerated and delivered online, making them accessible for career changers.

If you are looking for accessible entry points into nursing, consider exploring some of the easy nursing programs to get into. These programs often have lower admission barriers, making it easier for aspiring nurses to begin their education and career without extensive prerequisites.

Not everyone working in healthcare needs a clinical degree. Administrative roles such as medical billing and coding are in high demand. You can start your training at accredited medical billing and coding schools online with financial aid, providing both affordability and flexibility.

Additionally, aspiring nursing students often wonder about entrance exams. The answer to the question, do you have to take the teas test to get into nursing school, varies by program. Some schools do not require standardized entrance exams like TEAS or HESI, making the admission process smoother.

Best Scientists Citing Thierry Poynard

Trending Scientists

Recently Published Articles